Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00031993
Phase
PHASE2
Status
Completed

Conditions

  • Cervical Squamous Cell Carcinoma
  • Recurrent Cervical Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

Key Dates

First listed
Jan 27, 2003
Start date
Mar 31, 2002
Status verified
Jan 2013
Primary completion
Nov 30, 2005

Study Design

Enrollment
51 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (erlotinib hydrochloride)
    Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Progression-free survival [ Time Frame: At 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Gynecologic Oncology GroupPhiladelphiaPennsylvania19103-

Find similar trials in Philadelphia, PA

By research site
Gynecologic Oncology Group· Philadelphia, PA

Related Studies